Asia-Pacific Continuous Glucose Monitoring Market Size

Asia Pacific Continuous Glucose Monitoring (CGM) Market Analysis

The Asia-Pacific Continuous Glucose Monitoring Market size is estimated at USD 1.06 billion in the current year and is expected to reach USD 2.01 billion by the forecast year, growing at a CAGR of 11.74% during the forecast period.

The COVID-19 pandemic positively impacted the Asia-Pacific Diabetes Care Devices Market growth. Patients with diabetes, infected with COVID-19 may experience elevated blood glucose, abnormal glucose variability, and diabetic complications. The prevalence of diabetes in people with COVID-19 caused a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcomes. To avoid aggravation, a patient's blood glucose should be monitored regularly, which has underlined the importance of blood glucose monitoring devices. The pandemic emergency has created a rise in remote care from both patients and providers and removed many long-standing regulatory barriers.

According to International Diabetes Federation (IDF), 90 million adults (20-79) are living with diabetes in the IDF South-East Asia (SEA) Region in 2021. This figure is estimated to increase to 152 million by 2045 and 206 million adults (20-79) are living with diabetes in the IDF Western Pacific Region in 2021 which is estimated to increase to 260 million by 2045. The main diagnosis for diabetes patients is imbalances in blood glucose levels, which are not in compliance with the standard blood glucose levels. The general lab diagnostic tests can only help to diagnose the disease by physicians. Patients with more fluctuations in glucose levels need to get it checked every day. Patients administering insulin need to check their blood glucose levels frequently, adjust the doses of insulin, or change the medication, if necessary.

The incidence of newly diagnosed cases of Type 1 and Type 2 diabetes is observed to be on the rise, primarily attributed to factors such as obesity, unhealthy dietary habits, and lack of physical activity. The escalating frequency and pervasiveness of diabetic patients and healthcare expenses in developed nations are indicative of the growing utilization of diabetic care products. Furthermore, the mounting adoption of insulin delivery devices and the surging prevalence of diabetes are propelling the expansion of the market. Prominent manufacturers are directing their efforts towards technological advancements and the creation of sophisticated products to secure a significant market share.